BioKDE: Biomedical Knowledge Discovery Engine

Contact Us Login
Sorted by:  
Results by Year
Article Type
Publication date
  2,004,957 results (0.034 seconds)
1
Breast cancer.
Nadia Harbeck, Frédérique Penault-Llorca, +6 authors, Fatima Cardoso.
Nat Rev Dis Primers. 2019 Sep 23; 5(1):66. PMID: 31548545
Highly Cited. Review.
2
Breast cancer.
Sibylle Loibl, Philip Poortmans, +2 authors, Giuseppe Curigliano.
Lancet. 2021 Apr 01; 397(10286):1750-1769. PMID: 33812473
Review.
3
Breast cancer.
Nadia Harbeck,  Michael Gnant.
Lancet. 2016 Nov 17; 389(10074):1134-1150. PMID: 27865536
Highly Cited. Review.
4
Breast Cancer in Men.
Sharon H Giordano.
N Engl J Med. 2018 Jun 14; 378(24):2311-2320. PMID: 29897847
Highly Cited. Review.
5
HER2-positive breast cancer.
Sibylle Loibl,  Luca Gianni.
Lancet. 2016 Dec 07; 389(10087):2415-2429. PMID: 27939064
Highly Cited. Review.
6
Key steps for effective breast cancer prevention.
Kara L Britt,  Jack Cuzick,  Kelly-Anne Phillips.
Nat Rev Cancer. 2020 Jun 11; 20(8):417-436. PMID: 32528185
Review.
7
HER2-targeted therapies - a role beyond breast cancer.
Do-Youn Oh,  Yung-Jue Bang.
Nat Rev Clin Oncol. 2019 Sep 23; 17(1):33-48. PMID: 31548601
Review.
8
Cancer-associated adipocytes: key players in breast cancer progression.
Qi Wu, Bei Li, +3 authors, Shengrong Sun.
J Hematol Oncol. 2019 Sep 10; 12(1):95. PMID: 31500658     Free PMC article
Highly Cited. Review.
9
Targeting Cancer Stem Cells in Triple-Negative Breast Cancer.
So-Yeon Park,  Jang-Hyun Choi,  Jeong-Seok Nam.
Cancers (Basel). 2019 Jul 09; 11(7):. PMID: 31324052     Free PMC article
Highly Cited. Review.
10
Breast Cancer Immunotherapy: Facts and Hopes.
Leisha A Emens.
Clin Cancer Res. 2017 Aug 11; 24(3):511-520. PMID: 28801472     Free PMC article
Highly Cited. Review.
11
Targeting the PI3-kinase pathway in triple-negative breast cancer.
J Pascual,  N C Turner.
Ann Oncol. 2019 May 06; 30(7):1051-1060. PMID: 31050709
Highly Cited. Review.
12
Wnt signaling in triple-negative breast cancer.
Sö-G Pohl, N Brook, +3 authors, A Dharmarajan.
Oncogenesis. 2017 Apr 03; 6(4):e310. PMID: 28368389     Free PMC article
Highly Cited. Review.
13
Towards personalized treatment for early stage HER2-positive breast cancer.
Kristina Goutsouliak, Jamunarani Veeraraghavan, +4 authors, Rachel Schiff.
Nat Rev Clin Oncol. 2019 Dec 13; 17(4):233-250. PMID: 31836877     Free PMC article
Review.
14
Epithelial-Mesenchymal Transition and Breast Cancer.
Yanyuan Wu,  Marianna Sarkissyan,  Jaydutt V Vadgama.
J Clin Med. 2016 Jan 26; 5(2):. PMID: 26821054     Free PMC article
Highly Cited. Review.
15
Breast cancer in China.
Lei Fan, Kathrin Strasser-Weippl, +6 authors, Paul E Goss.
Lancet Oncol. 2014 May 30; 15(7):e279-89. PMID: 24872111
Highly Cited. Review.
16
Progress in adjuvant systemic therapy for breast cancer.
Noam F Pondé,  Dimitrios Zardavas,  Martine Piccart.
Nat Rev Clin Oncol. 2018 Sep 13; 16(1):27-44. PMID: 30206303
Review.
17
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance.
Sonia Pernas,  Sara M Tolaney.
Ther Adv Med Oncol. 2019 Mar 19; 11:1758835919833519. PMID: 30911337     Free PMC article
Highly Cited. Review.
18
Triple-negative breast cancer.
William D Foulkes,  Ian E Smith,  Jorge S Reis-Filho.
N Engl J Med. 2010 Nov 12; 363(20):1938-48. PMID: 21067385
Highly Cited. Review.
19
Immunotherapy and targeted therapy combinations in metastatic breast cancer.
Francisco J Esteva,  Vanessa M Hubbard-Lucey,  Jun Tang,  Lajos Pusztai.
Lancet Oncol. 2019 Mar 08; 20(3):e175-e186. PMID: 30842061
Highly Cited. Review.
20
Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications.
Nishant Gandhi,  Gokul M Das.
Cells. 2019 Jan 26; 8(2):. PMID: 30691108     Free PMC article
Highly Cited. Review.
1 2 3 4 5 6 7 8 9 10 Next